3Brain

Executive Summary

3Brain AG is a Swiss neurotechnology company specializing in high-density microelectrode arrays (HD-MEAs) for in vitro electrophysiology. Founded in 2010 and headquartered in Zug, the company provides advanced tools that enable label-free, real-time recording of neuronal activity, supporting drug discovery, functional assays, and fundamental neuroscience research. Its HD-MEA platforms offer superior spatial and temporal resolution compared to traditional electrophysiology methods, positioning 3Brain as a key enabler in the shift toward more predictive preclinical models. The company's technology is particularly relevant for neurological disease modeling, cardiotoxicity screening, and the development of next-generation therapeutics. While private and without disclosed funding or valuation, 3Brain has established a presence in the biopharma market through distributor relationships and direct sales to academic and industry labs.

Upcoming Catalysts (preview)

• Q3 2026Launch of automated HD-MEA platform for high-throughput screening60% success
• H2 2026Strategic partnership with major pharmaceutical company for CNS drug screening40% success
• 2026Series B funding round to scale manufacturing and commercial expansion50% success